GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

  • End date
    Dec 15, 2023
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 15 February 2022
cell transplantation
b-cell lymphoma


The purpose of this multi-center,single arm,phase clinical trail is to determine the safety and efficacy of GVDR (gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab) regimen for autologous hematopoietic stem cell transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell lymphoma.

Condition Lymphoma, Large B-Cell, Diffuse
Treatment gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab
Clinical Study IdentifierNCT04021992
SponsorSun Yat-sen University
Last Modified on15 February 2022


Yes No Not Sure

Inclusion Criteria

biopsy proved CD20+ DLBCL
previously received at least one systemic treatment (including chemotherapy) without remission or relapse after remission
at least one evaluable lesion
-65 years
proper functioning of the major organs

Exclusion Criteria

involvement of central nervous system
with other malignancy
patients receiving or received drug of other clinical trial within 30 days
previously received doxorubicin liposome or have used other anthracycline drug with accumulated restricted doses (adriamycin 450mg/m2, epirubicin 935mg/m2, acrarubicin 900mg/m2)
patients who received treatment for hematologic toxicity caused by previous chemotherapy within 7 days before enrollment
grade 2 or more peripheral neuropathy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note